UNILEVER TAKEOVER BID FOR RICH-VICKS SENDS STOCK UP 8 POINTS; INDEX MOVES DOWN
Univlever's interest pushed Rich-Vicks up for the second week in a row (plus 8 to 48). The issue's nearly 12 point rise during the last 10 trading days has increased the company's market value by more than 30%. Rich-Vicks was one of the few exceptions to the overall downward trend that stocks listed on the "F-D-C" Index exhibited for the week ended Sept. 13. The Composite continued to fall at a more rapid pace than the Dow Jones average, which closed at 1307.68, down roughly 28 points for the week. Pharmaceutical stocks were hit particularly hard, with only one issue out of 17, Rorer (up 5/8 to 39-1/4), showing any upward movement. Multi-point losers included Upjohn (down 3-3/4 to 105), Schering-Plough (down 31/8 to 45-5/8) and Merck (down 2-1/4 to 11-1/4). Chart omitted.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth